These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 28677896)

  • 1. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Dang NH; Ogura M; Castaigne S; Fayad LE; Jerkeman M; Radford J; Pezzutto A; Bondarenko I; Stewart DA; Shnaidman M; Sullivan S; Vandendries E; Tobinai K; Ramchandren R; Hamlin PA; Giné E; Ando K
    Br J Haematol; 2018 Aug; 182(4):583-586. PubMed ID: 28677896
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
    Ogura M; Tobinai K; Hatake K; Davies A; Crump M; Ananthakrishnan R; Ishibashi T; Paccagnella ML; Boni J; Vandendries E; MacDonald D
    Clin Cancer Res; 2016 Oct; 22(19):4807-4816. PubMed ID: 27154915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Ogura M; Hatake K; Ando K; Tobinai K; Tokushige K; Ono C; Ishibashi T; Vandendries E
    Cancer Sci; 2012 May; 103(5):933-8. PubMed ID: 22335424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
    Fayad L; Offner F; Smith MR; Verhoef G; Johnson P; Kaufman JL; Rohatiner A; Advani A; Foran J; Hess G; Coiffier B; Czuczman M; Giné E; Durrant S; Kneissl M; Luu KT; Hua SY; Boni J; Vandendries E; Dang NH
    J Clin Oncol; 2013 Feb; 31(5):573-83. PubMed ID: 23295790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
    Goy A; Forero A; Wagner-Johnston N; Christopher Ehmann W; Tsai M; Hatake K; Ananthakrishnan R; Volkert A; Vandendries E; Ogura M
    Br J Haematol; 2016 Aug; 174(4):571-81. PubMed ID: 27101934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotuzumab Ozogamicin: First Global Approval.
    Lamb YN
    Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy.
    Ogura M; Tobinai K; Hatake K; Uchida T; Kasai M; Oyama T; Suzuki T; Kobayashi Y; Watanabe T; Azuma T; Mori M; Terui Y; Yokoyama M; Mishima Y; Takahashi S; Ono C; Ohata J
    Cancer Sci; 2010 Aug; 101(8):1840-5. PubMed ID: 20491780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Wagner-Johnston ND; Goy A; Rodriguez MA; Ehmann WC; Hamlin PA; Radford J; Thieblemont C; Suh C; Sweetenham J; Huang Y; Sullivan ST; Vandendries ER; Gisselbrecht C
    Leuk Lymphoma; 2015; 56(10):2863-9. PubMed ID: 25707288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
    Pirosa MC; Zhang L; Hitz F; Novak U; Hess D; Terrot T; Pascale M; Mazzucchelli L; Bertoni F; Cavalli F; Zucca E; Stathis A
    Leuk Lymphoma; 2022 Jan; 63(1):117-123. PubMed ID: 34407735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
    Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
    J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
    Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
    Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
    Hüttmann A; Rekowski J; Müller SP; Hertenstein B; Franzius C; Mesters R; Weckesser M; Kroschinsky F; Kotzerke J; Ganser A; Bengel FM; La Rosée P; Freesmeyer M; Höffkes HG; Hertel A; Behringer D; Prange-Krex G; Griesshammer M; Holzinger J; Wilop S; Krohn T; Raghavachar A; Maschmeyer G; Brink I; Schroers R; Gaska T; Bernhard H; Giagounidis A; Schütte J; Dienst A; Hautzel H; Naumann R; Klein A; Hahn D; Pöpperl G; Grube M; Marienhagen J; Schwarzer A; Kurch L; Höhler T; Steiniger H; Nückel H; Südhoff T; Römer W; Brinkmann M; Ose C; Alashkar F; Schmitz C; Dürig J; Hoelzer D; Jöckel KH; Klapper W; Dührsen U
    Ann Hematol; 2019 Apr; 98(4):897-907. PubMed ID: 30610279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
    Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
    Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).
    Witzig TE; Johnston PB; LaPlant BR; Kurtin PJ; Pederson LD; Moore DF; Nabbout NH; Nikcevich DA; Rowland KM; Grothey A
    Am J Hematol; 2017 Oct; 92(10):1004-1010. PubMed ID: 28614905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Jain N; O'Brien S; Thomas D; Kantarjian H
    Front Biosci (Elite Ed); 2014 Jan; 6(1):40-5. PubMed ID: 24389139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Garrett M; Ruiz-Garcia A; Parivar K; Hee B; Boni J
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):211-222. PubMed ID: 30859374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab subcutaneous in B-cell non-Hodgkin lymphoma: clinical experience in a single center.
    Sanchez-Gonzalez B; Torres E; Ferraro Rosset MP; Calafell M; Gale C; Martinez L; Sancho E; Garcia P; Gimeno E; Garcia-Pallarols F; Salar A
    Leuk Lymphoma; 2018 Apr; 59(4):1019-1021. PubMed ID: 28728440
    [No Abstract]   [Full Text] [Related]  

  • 19. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
    N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
    Choudhry A; O'Brien SM
    Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.